研究業績（原著論文のみ）/ Publications(Original Articles only)
2025年度
Clonal Complexity Defines Distinct Tumor-Intrinsic Biology and Prognosis in Diffuse Large B-Cell Lymphoma.
Haeno T, Sakai K, Minamoto S, Nakatsu D, De Velasco MA, Rai S, Tanaka H, Matsumura I, Nishio K.
Cancer Med
. 2026 Feb;15(2):e71597. doi: 10.1002/cam4.71597.
A case of endometrioid carcinoma of the endometrium that progressed to lethal neuroendocrine carcinoma as a result of TMEM178B-BRAF fusion.
Kashima Y, Takaya H, Miyagawa C, Otani T, Sakai K, Nishio K, Matsumura N.
Int Cancer Conf J
. 2025 Nov 8;15(1):99-102. doi: 10.1007/s13691-025-00823-5. eCollection 2026 Jan.
Long-term progression-free survivors ("super responders") to olaparib maintenance in recurrent ovarian cancer: a multicenter real-world study (KCOG-G2101s).
Fukuda N, Takashima T, Nakai H, Yoshioka E, Ito K, Taniguchi R, Tsubamoto H, Motohashi T, Fujiwara S, Katsuda T, Nishio S, Nagano H, Nishikawa R, Kai K, Arakawa A, Sakai K, Morii E, Nishio K, Matsumura N.
Int J Clin Oncol
. 2026 Feb;31(2):310-318. doi: 10.1007/s10147-025-02942-8. Epub 2025 Dec 22.
RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC.
Nishio M, Seto T, Reck M, Garon EB, Nishio K, Kasahara K, Nishino K, Satouchi M, Yoh K, Hayashi H, Sakai K, Enatsu S, Matsui T, Varughese SC, Carlsen M, Visseren-Grul C, Nakagawa K.
JTO Clin Res Rep
. 2025 Sep 26;6(12):100912. doi: 10.1016/j.jtocrr.2025.100912. eCollection 2025 Dec.
Zongertinib, a Novel HER2 Tyrosine Kinase Inhibitor, Maintains an Anticancer Activity for Trastuzumab Deruxtecan-Resistant Cancers Harboring HER2-Overexpression.
Kurosaki T, Suzuki S, Yonesaka K, Kawanaka Y, Takehara T, Teramura T, Sakai K, Nishio K, Hayashi H.
Int J Mol Sci
. 2025 Oct 29;26(21):10515. doi: 10.3390/ijms262110515.
Ovarian Epithelioid Tumor With FUS::CREM Fusion in a 63-Year-Old Woman: A Case Report of an Emerging Entity Associated With Systemic Inflammation.
Kajiyama H, Kashima Y, Otani T, Sakai K, Shiraishi N, Nishio K, Shishido-Hara Y, Ito A, Minamiguchi S, Matsumura N.
Int J Gynecol Pathol
. 2025 Oct 2. doi: 10.1097/PGP.0000000000001142. Online ahead of print.
Cure of Recurrent Ovarian Cancer: A Multicenter Retrospective Study.
Sumitomo M, Kotani Y, Murakami K, Abiko K, Sakai K, Otani T, Ueda A, Ukita M, Taga A, Emoto I, Sekiyama K, Okudate M, Matsubara M, Yamanishi Y, Nishio K, Mandai M, Matsumura N.
Cancers (Basel)
. 2025 Sep 19;17(18):3069. doi: 10.3390/cancers17183069.
Case Report: A small cell lung cancer transformed from an EGFR-mutated Adenocarcinoma demonstrated a long-term remission to anti PD-1 antibody.
Kawanaka Y, Yonesaka K, Tanizaki J, Maenishi O, Sakai K, Kakimi K, Nishio K, Hayashi H.
Front Oncol
. 2025 Sep 10:15:1651248. doi: 10.3389/fonc.2025.1651248. eCollection 2025.
RELAY: safety and efficacy of ramucirumab plus erlotinib in elderly Japanese patients with metastatic EGFR-mutated NSCLC.
Nishino K, Seto T, Nishio M, Nishio K, Kasahara K, Satouchi M, Yoh K, Hayashi H, Enatsu S, Matsui T, Varughese SC, Visseren-Grul C, Nakagawa K.
Future Oncol
. 2025 Oct;21(24):3197-3206. doi: 10.1080/14796694.2025.2560225. Epub 2025 Sep 25.
Evaluation of Telomerase Reverse Transcriptase (TERT) Promoter Mutations in Photodynamic Diagnosis With 5-Aminolevulinic Acid False-Positive Sites in Non-muscle-Invasive Bladder Cancer.
Saito Y, Adomi S, Sakai K, Antonio De Velasco M, Hashimoto M, Banno E, Hayashi Y, Minami T, Nishio K, Fujita K.
Cureus
. 2025 Aug 24;17(8):e90860. doi: 10.7759/cureus.90860. eCollection 2025 Aug.
Biological impact of chemotherapy during treatment with EGFR tyrosine kinaseinhibitors for non-small cell lung cancer positive for EGFR activating mutations.
Iwama E, Sakai K, Harada T, Kanda S, Sugawara S, Yokoyama T, Taniguchi H, Tanaka K, Toyozawa R, Koyama K, Zenke Y, Kida G, Nishioka Y, Yokouchi H, Hirose M, Nishio K, Yamamoto N, Ohe Y, Okamoto I.
Lung Cancer
. 2025 Oct:208:108756. doi: 10.1016/j.lungcan.2025.108756. Epub 2025 Sep 16.
A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation-positive non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B study.
Nagashima H, Fukuhara T, Utsumi Y, Suzuki A, Miyanaga A, Seike M, Azuma K, Asahina H, Kisohara A, Kawashima Y, Tanaka H, Kanemaru R, Miyauchi E, Furuya N, Sato H, Nakashima K, Watanabe S, Sakai K, Nishio K, Takahashi F, Kobayashi K, Maemondo M.
European Journal of Cancer
. 2025 Oct 16:229:115693. doi: 10.1016/j.ejca.2025.115693. Epub 2025 Aug 20.
Efficacy of Conventional and Novel Tyrosine Kinase Inhibitors for Uncommon EGFR Mutations-An In Vitro Study.
Oiki H, Suda K, Hamada A, Fujino T, Obata K, Kobayashi Y, Sakai K, Fukuda S, Ohara S, Ito M, Soh J, Nishio K, Mitsudomi T, Tsutani Y.
Cells
. 2025 Sep 4;14(17):1386. doi: 10.3390/cells14171386.
Impact of B7-H3 and DLL3 expression on the efficacy of PD-L1 blockade therapy in extensive-stage small cell lung cancer.
Kurosaki T, Kanemura H, Otani T, Kawanaka Y, Fukuda Y, Kudo K, Tanizaki J, Suzuki S, Tomida S, Sakai K, Chiba Y, Ito A, Nishio K, Nakagawa K, Hayashi H.
Lung Cancer
. 2025 Sep:207:108723. doi: 10.1016/j.lungcan.2025.108723. Epub 2025 Aug 23.
Synchronous endometrial and ovarian cancers originating from distinct clonal lineages in Lynch syndrome: A case report and review of the literature.
Ohta M, Murakami K, Otani T, Sakai K, Nishio K, Matsumura N.
J Obstet Gynaecol Res
. 2025 Jul;51(7):e70003. doi: 10.1111/jog.70003.
Comparison of genetic mutations in bladder cancers that arose following radiotherapy for prostate cancer with those in primary bladder cancers.
Adomi S, Sakai K, Kura Y, De Velasco MA, Fujimoto S, Toyoda S, Hashimoto M, Nishimoto M, Banno E, Saito Y, Sugimoto K, Hayashi Y, Minami T, Yoshimura K, Uemura H, Nishio K, Fujita K.
Scientific reports
. 2025 Jul 1;15(1):20495. doi: 10.1038/s41598-025-05149-z.
Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese Subset.
Nishio M, Seto T, Reck M, Garon EB, Nishio K, Kasahara K, Nishino K, Satouchi M, Yoh K, Hayashi H, Sakai K, Enatsu S, Frimodt-Møller B, Matsui T, Varughese SC, Carlsen M, Visseren-Grul C, Nakagawa K.
JTO Clin Res Rep
. 2025 Feb 28;6(6):100819. doi: 10.1016/j.jtocrr.2025.100819. eCollection 2025 Jun.
Exploration of genes related to the development of cancer of unknown primary.
Fujita Y, De Velasco MA, Hayashi H, Nakagawa K, Nishio K.
Oncol Rep
. 2025 Jun;53(6):72. doi: 10.3892/or.2025.8905. Epub 2025 May 2.
2024年度
Malignant transformation of an ovarian mature teratoma diagnosed 17 years ago: a case report and literature review of treatment with immune checkpoint inhibitors.
Nagayama A, Miyagawa C, Kashima Y, Ohta M, Otani T, Kurosaki T, Isomoto K, Inagaki C, Takahama T, Yonesaka K, Hayashi H, Sakai K, Nishio K, Nakagawa K, Matsumura N.
Int Cancer Conf J
. 2024 Dec 19;14(2):85-90. doi: 10.1007/s13691-024-00740-z. eCollection 2025 Apr.
Chromosomal Instability Is Associated with cGAS–STING Activation in EGFR-TKI Refractory Non-Small-Cell Lung Cancer.
Yonesaka K, Kurosaki T, Tanizaki J, Kawakami H, Tanaka K, Maenishi O, Takamura S, Sakai K, Chiba Y, Teramura T, Goto H, Otsuka E, Okida H, Funabashi M, Hashimoto Y, Hirotani K, Kamai Y, Kagari T, Nishio K, Kakimi K, Hayashi H.
Cells
. 2025 Mar 17;14(6):447. doi: 10.3390/cells14060447.
Molecular Classification of Hepatocellular Carcinoma based on Zoned Metabolic Feature and Oncogenic Signaling Pathway.
Aoki T, Nishida N, Kurebayashi Y, Sakai K, Fujiwara N, Tsurusaki M, Hanaoka K, Morita M, Chishina H, Takita M, Hagiwara S, Ida H, Ueshima K, Minami Y, Takebe A, Murase T, Kamei K, Nakai T, Matsumoto I, Nishio K, Kudo M.
Clin Mol Hepatol
. 2025 Mar 11. doi: 10.3350/cmh.2024.1088. Online ahead of print.
Detection of Overlooked Rare EGFR Mutations in Non-small Cell Lung Cancer Using Multigene Testing.
Shiraishi N, Takahama T, Sakai K, Tanaka K, Nakagawa Y, Kanemura H, Nakayama T, Kawanaka Y, Kurosaki T, Suzuki S, Iwasa T, Tanizaki J, Inagaki C, Yonesaka K, Fukuoka K, Mitsudomi T, Nishio K, Hayashi H, Nakagawa K.
Thorac Cancer
. 2025 Feb;16(3):e70007. doi: 10.1111/1759-7714.70007.
Efficacy of ramucirumab combined with erlotinib or osimertinib in untreated EGFR-mutated NSCLC patients with asymptomatic brain metastases: insights from molecular biomarkers in the RELAY-brain trial.
Kaneda H, Daga H, Okada A, Nakatani Y, Tani Y, Oka T, Sawa K, Sakai K, Nishio K, Kawaguchi T.
Invest New Drugs
. 2025 Feb;43(1):147-156. doi: 10.1007/s10637-025-01505-y. Epub 2025 Jan 23.
Dual single‑nucleotide polymorphism biomarker combination for opioid selection to treat cancer pain.
Fujita Y, Matsuoka H, Chiba Y, Tsurutani J, Yoshida T, Sakai K, Nakura M, Sakamoto R, Makimura C, Ohtake Y, Tanaka K, Hayashi H, Takahama T, Tanizaki J, Koyama A, Nishio K, Nakagawa K.
Mol Clin Oncol
. 2024 Nov 29;22(2):14. doi: 10.3892/mco.2024.2809. eCollection 2025 Feb.
Final Analysis Data and Exploratory Biomarker Analysis of a Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib Monotherapy for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: The WJOG9717L Study.
Kenmotsu H, Sakai K, Mori K, Kato T, Sugawara S, Kirita K, Yoneshima Y, Azuma K, Nishino K, Teraoka S, Koyama R, Masuda K, Hayashi H, Toyozawa R, Miura S, Sato Y, Nakagawa K, Yamamoto N, Nishio K, Takahashi T.
JTO Clin Res Rep
. 2024 Aug 23;5(11):100716. doi: 10.1016/j.jtocrr.2024.100716. eCollection 2024 Nov.
Afatinib plus bevacizumab combination after osimertinib resistance in advanced EGFR-mutant non-small cell lung cancer: Phase II ABCD-study.
Hata A, Katakami N, Takase N, Kibata K, Yamanaka Y, Tamiya M, Mori M, Kijima T, Morita S, Sakai K, Nishio K.
Lung Cancer
. 2024 Nov:197:107988. doi: 10.1016/j.lungcan.2024.107988. Epub 2024 Oct 5.
A machine learning-based method for feature reduction of methylation data for the classification of cancer tissue origin
De Velasco MA, Sakai K, Mitani S, Kura Y, Minamoto S, Haeno T, Hayashi H, Nishio K.
Int J Clin Oncol
. 2024 Dec;29(12):1795-1810. doi: 10.1007/s10147-024-02617-w. Epub 2024 Sep 18.
Improved platelet separation performance from whole blood using an acoustic fluidics system
Sakai, Kazuko; Ohara, Shuta; Tanaka, Junko; Suda, Kenichi; Muramatsu, Takamichi; Uematsu, Chihiro; Tsutani, Yasuhiro; Mitsudomi, Tetsuya; Nishio, Kazuto.
Cancer Sci
. 2024 Nov;115(11):3795-3803. doi: 10.1111/cas.16337. Epub 2024 Sep 22.
Different characteristics of the tumor immune microenvironment among subtypes of salivary gland cancer
Nagatani Y, Kiyota N, Imamura Y, Koyama T, Funakoshi Y, Komatsu M, Itoh T, Teshima M, Nibu KI, Sakai K, Nishio K, Shimomura M, Nakatsura T, Ikarashi D, Nakayama T, Kitano S, Minami H.
Asia Pac J Clin Oncol
. 2024 Sep 4. doi: 10.1111/ajco.14108. Online ahead of print.
Exploring the relationship between ulcerative colitis, colorectal cancer, and prostate cancer
Kura Y, De Velasco MA, Sakai K, Uemura H, Fujita K, Nishio K.
Hum Cell
. 2024 Aug 20. doi: 10.1007/s13577-024-01118-2. Online ahead of print.
A cross-species analysis of fecal microbiomes in humans and mice reveals similarities and dissimilarities associated with prostate cancer risk
Wakamori C, De Velasco MA, Sakai K, Kura Y, Matsushita M, Fujimoto S, Hatano K, Nonomura N, Fujita K, Nishio K, Uemura H.
Prostate
. 2024 Aug 7. doi: 10.1002/pros.24776. Online ahead of print.
Two Distinct Characteristics of Immune Microenvironment in Human Hepatocellular Carcinoma with Wnt/β-Catenin Mutations
Aoki T, Nishida N, Kurebayashi Y, Sakai K, Morita M, Chishina H, Takita M, Hagiwara S, Ida H, Ueshima K, Minami Y, Tsurusaki M, Nakai T, Sakamoto M, Nishio K, Kudo M.
Liver Cancer
. 2023 Oct 9;13(3):285-305. doi: 10.1159/000533818. eCollection 2024 Jun.
Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer
Haratani K, Nakamura A, Mamesaya N, Sawa K, Shiraishi Y, Saito R, Tanizaki J, Tamura Y, Hata A, Tsuruno K, Sakamoto T, Teraoka S, Oki M, Watanabe H, Tokito T, Nagata K, Masuda T, Nakamura Y, Sakai K, Chiba Y, Ito A, Nishio K, Yamamoto N, Nakagawa K, Hayashi H.
Br J Cancer
. 2024 May;130(11):1783-1794. doi: 10.1038/s41416-024-02662-2. Epub 2024 Mar 22.
The Tumor Immune Microenvironment Is Associated With Recurrence in Early-Stage Lung Adenocarcinoma
Kanemura H, Yokoyama T, Nakajima R, Nakamura A, Kuroda H, Kitamura Y, Shoda H, Mamesaya N, Miyata Y, Okamoto T, Okishio K, Oki M, Sakairi Y, Chen-Yoshikawa TF, Aoki T, Ohira T, Matsumoto I, Ueno K, Miyazaki T, Matsuguma H, Yokouchi H, Otani T, Ito A, Sakai K, Chiba Y, Nishio K, Yamamoto N, Okamoto I, Nakagawa K, Takeda M.
JTO Clin Res Rep
. 2024 Mar 8;5(4):100658. doi: 10.1016/j.jtocrr.2024.100658. eCollection 2024 Apr.
Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade
Hayashi H, Chamoto K, Hatae R, Kurosaki T, Togashi Y, Fukuoka K, Goto M, Chiba Y, Tomida S, Ota T, Haratani K, Takahama T, Tanizaki J, Yoshida T, Iwasa T, Tanaka K, Takeda M, Hirano T, Yoshida H, Ozasa H, Sakamori Y, Sakai K, Higuchi K, Uga H, Suminaka C, Hirai T, Nishio K, Nakagawa K, Honjo T.
J Clin Invest
. 2024 Apr 1;134(7):e168318. doi: 10.1172/JCI168318.
TP53 and/or BRCA1 Mutations Based on CtDNA Analysis as Prognostic Biomarkers for Primary Triple-Negative Breast Cancer
Arimura A, Sakai K, Kaneshiro K, Morisaki T, Hayashi S, Mizoguchi K, Yamada M, Kai M, Ono M, Nishio K, Nakamura M, Kubo M.
Cancers (Basel)
. 2024 Mar 18;16(6):1184. doi: 10.3390/cancers16061184.
ACA-28, an ERK MAPK Signaling Modulator, Exerts Anticancer Activity through ROS Induction in Melanoma and Pancreatic Cancer Cells
Takasaki T, Hamabe Y, Touchi K, Khandakar GI, Ueda T, Okada H, Sakai K, Nishio K, Tanabe G, Sugiura R.
Oxid Med Cell Longev
. 2024 Mar 11:2024:7683793. doi: 10.1155/2024/7683793. eCollection 2024.